Literature DB >> 32289231

Lung Function Trajectories Leading to Chronic Obstructive Pulmonary Disease as Predictors of Exacerbations and Mortality.

Jacob Louis Marott1, Truls Sylvan Ingebrigtsen1, Yunus Çolak1,2, Jørgen Vestbo3,4, Peter Lange1,5,6.   

Abstract

Rationale: Chronic obstructive pulmonary disease (COPD) can develop not only through a lung function trajectory dominated by an accelerated decline of FEV1 from normal maximally attained FEV1 in early adulthood (normal maximally attained FEV1 trajectory) but also through a trajectory with FEV1 below normal in early adulthood (low maximally attained FEV1 trajectory).
Objectives: To test whether the long-term risk of exacerbations and mortality differs between these two subtypes of COPD.
Methods: The cohort included 1,170 young adults enrolled in the Copenhagen City Heart Study during the 1970s and 1980s. In 2001-2003, which served as the baseline for the present analyses, 79 participants had developed COPD through normal maximally attained FEV1 trajectory, 65 had developed COPD through low maximally attained FEV1 trajectory, and 1,026 did not have COPD.Measurements and Main
Results: From 2001 until 2018, we observed 139 severe exacerbations of COPD and 215 deaths, of which 55 were due to nonmalignant respiratory disease. In Cox models, there was no difference with regard to risk of severe exacerbations between the two trajectories, but individuals with normal maximally attained FEV1 had an increased risk of nonmalignant respiratory disease mortality (using inverse probability of censoring weighting with adjusted hazard ratio [HR], 6.20; 95% confidence interval [CI], 2.09-18.37; P = 0.001) and all-cause mortality (adjusted HR, 1.93; 95% CI, 1.14-3.26; P = 0.01) compared with individuals with low maximally attained FEV1.Conclusions: COPD developed through normal maximally attained FEV1 trajectory is associated with an increased risk of respiratory and all-cause mortality compared with COPD developed through low maximally attained FEV1 trajectory.

Entities:  

Keywords:  chronic obstructive pulmonary disease (COPD); exacerbations; mortality; trajectories

Mesh:

Year:  2020        PMID: 32289231      PMCID: PMC7365378          DOI: 10.1164/rccm.201911-2115OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  29 in total

1.  Lung function decline and outcomes in an adult population.

Authors:  David M Mannino; Matthew M Reichert; Kourtney J Davis
Journal:  Am J Respir Crit Care Med       Date:  2006-01-26       Impact factor: 21.405

2.  The natural history of chronic airflow obstruction.

Authors:  C Fletcher; R Peto
Journal:  Br Med J       Date:  1977-06-25

3.  Low Lung Function in Young Adult Life Is Associated with Early Mortality.

Authors:  Monica M Vasquez; Muhan Zhou; Chengcheng Hu; Fernando D Martinez; Stefano Guerra
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

4.  The Copenhagen City Heart Study. Osterbroundersøgelsen. A book of tables with data from the first examination (1976-78) and a five year follow-up (1981-83). The Copenhagen City Heart Study Group.

Authors: 
Journal:  Scand J Soc Med Suppl       Date:  1989

5.  Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study.

Authors:  Mette Thomsen; Børge G Nordestgaard; Jørgen Vestbo; Peter Lange
Journal:  Lancet Respir Med       Date:  2013-07-29       Impact factor: 30.700

6.  Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis.

Authors:  Peter Lange; Yunus Çolak; Truls Sylvan Ingebrigtsen; Jørgen Vestbo; Jacob Louis Marott
Journal:  Lancet Respir Med       Date:  2016-04-06       Impact factor: 30.700

7.  Changes in forced expiratory volume in 1 second over time in COPD.

Authors:  Jørgen Vestbo; Lisa D Edwards; Paul D Scanlon; Julie C Yates; Alvar Agusti; Per Bakke; Peter M A Calverley; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William MacNee; Bruce E Miller; Edwin K Silverman; Ruth Tal-Singer; Emiel Wouters; Stephen I Rennard
Journal:  N Engl J Med       Date:  2011-09-26       Impact factor: 91.245

8.  Asthma, COPD and overlap syndrome: a longitudinal study in young European adults.

Authors:  Roberto de Marco; Alessandro Marcon; Andrea Rossi; Josep M Antó; Isa Cerveri; Thorarinn Gislason; Joachim Heinrich; Christer Janson; Deborah Jarvis; Nino Kuenzli; Bénédicte Leynaert; Nicole Probst-Hensch; Cecilie Svanes; Matthias Wjst; Peter Burney
Journal:  Eur Respir J       Date:  2015-06-25       Impact factor: 16.671

9.  Longitudinal Modeling of Lung Function Trajectories in Smokers with and without Chronic Obstructive Pulmonary Disease.

Authors:  James C Ross; Peter J Castaldi; Michael H Cho; Craig P Hersh; Farbod N Rahaghi; Gonzalo V Sánchez-Ferrero; Margaret M Parker; Augusto A Litonjua; David Sparrow; Jennifer G Dy; Edwin K Silverman; George R Washko; Raúl San José Estépar
Journal:  Am J Respir Crit Care Med       Date:  2018-10-15       Impact factor: 30.528

10.  Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions.

Authors:  Sigrun Alba Johannesdottir; Erzsébet Horváth-Puhó; Vera Ehrenstein; Morten Schmidt; Lars Pedersen; Henrik Toft Sørensen
Journal:  Clin Epidemiol       Date:  2012-11-12       Impact factor: 4.790

View more
  13 in total

1.  Update in Chronic Obstructive Pulmonary Disease 2020.

Authors:  Andy I Ritchie; Jonathon R Baker; Trisha M Parekh; James P Allinson; Surya P Bhatt; Louise E Donnelly; Gavin C Donaldson
Journal:  Am J Respir Crit Care Med       Date:  2021-07-01       Impact factor: 21.405

Review 2.  Chronic obstructive pulmonary disease risk assessment tools: is one better than the others?

Authors:  Jennifer M Wang; MeiLan K Han; Wassim W Labaki
Journal:  Curr Opin Pulm Med       Date:  2022-03-01       Impact factor: 3.155

3.  Characteristics and Prevalence of Early Chronic Obstructive Pulmonary Disease in a Middle-Aged Population: Results from a Nationwide-Representative Sample.

Authors:  Taeyun Kim; Jehun Kim; Jun Hyeong Kim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-11-12

4.  Is the GOLD guideline for diagnosing obstruction in COPD discriminatory in predicting severe future COPD-related exacerbations and death?

Authors:  Melissa J McDonnell; Michael Harrison; Robert M Rutherford
Journal:  Breathe (Sheff)       Date:  2021-12

5.  Longitudinal change in lung function and subsequent risks of cardiovascular events: evidence from four prospective cohort studies.

Authors:  Yun-Jiu Cheng; Zhen-Guang Chen; Zhu-Yu Li; Wei-Yi Mei; Wen-Tao Bi; Dong-Ling Luo
Journal:  BMC Med       Date:  2021-07-02       Impact factor: 8.775

6.  Serum Th-2 cytokines and FEV1 decline in WTC-exposed firefighters: A 19-year longitudinal study.

Authors:  Michael D Weiden; Ankura Singh; David G Goldfarb; Barbara Putman; Rachel Zeig-Owens; Theresa Schwartz; Hillel W Cohen; David J Prezant
Journal:  Am J Ind Med       Date:  2021-07-20       Impact factor: 3.079

7.  The Origins of Chronic Obstructive Pulmonary Disease: Sometimes the Journey Matters More than the Destination.

Authors:  William Z Zhang
Journal:  Am J Respir Crit Care Med       Date:  2020-07-15       Impact factor: 21.405

Review 8.  Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease.

Authors:  Kiki Waeijen-Smit; Sarah Houben-Wilke; Antonio DiGiandomenico; Ulf Gehrmann; Frits M E Franssen
Journal:  Intern Emerg Med       Date:  2021-02-22       Impact factor: 3.397

9.  Rate of Decline of FEV1 as a Biomarker of Survival?

Authors:  Alberto Papi; Bianca Beghé; Leonardo M Fabbri
Journal:  Am J Respir Crit Care Med       Date:  2021-03-15       Impact factor: 21.405

Review 10.  The Importance of Appropriate Diagnosis in the Practical Management of Chronic Obstructive Pulmonary Disease.

Authors:  Naozumi Hashimoto; Keiko Wakahara; Koji Sakamoto
Journal:  Diagnostics (Basel)       Date:  2021-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.